Every 424B that Allogene Therapeutics, Inc. (ALLO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ALLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALLO filings page.
Allogene Therapeutics filed a prospectus supplement to sell up to $135,000,000 of common stock through an at‑the‑market program with TD Securities (USA) LLC (TD Cowen) as sales agent. Sales may occur from time to time at market prices and TD Cowen’s commission is up to 3.0% of gross proceeds. The supplement references a last reported sale price of $2.00 per share on June 18, 2026 and states proceeds will be used for general corporate purposes, including clinical trials, R&D, G&A and capital expenditures. The company also amended its charter to increase authorized common shares to 800,000,000.
Allogene Therapeutics, Inc. is offering 87,500,000 shares of its common stock at a public offering price of $2.00 per share by prospectus supplement dated April 14, 2026. The underwriting agreement shows proceeds, before expenses, to Allogene of $164,500,000. The underwriters have a 30‑day option to purchase up to an additional 13,125,000 shares at the public price less underwriting discounts. The offering assumes delivery in New York on or about April 16, 2026. The number of shares outstanding immediately after this offering is based on 229,413,523 shares outstanding as of December 31, 2025.
Allogene Therapeutics is offering $175,000,000 of common stock. The prospectus supplement registers an offering of common stock with a 30-day underwriter option to purchase an additional $26,250,000 of shares. The offering references a recent market price of $2.72 per share (last reported April 10, 2026).
Separately, Allogene reported interim futility analysis data from the randomized Phase 2 ALPHA3 trial in 1L consolidation LBCL: among the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm were MRD negative at last assessment versus 16.7% (2/12) in observation, an absolute difference of 41.6%. Safety signals in this cohort showed no CRS, ICANS or GvHD events of special interest. The company expects ~220 total patients, interim EFS analysis in mid-2027 and primary EFS analysis in mid-2028.